Home Stocks NVCR Novocure Ltd (NASDAQ: NVCR) Healthcare · Medical Devices
$10.73 −0.41 (−3.68%)
Last close · Nov 18, 2026 · NASDAQ USD
The Quantellect read. NVCR fell 3.68% in the Nov 18 session to $10.73, which is 46.3% below its 52-week high of $19.99. Short interest is 13.26% of float with a 0.41% borrow fee. Five active firms cover the stock as of Nov 19, 2026; five active firms with targets average $25.20 over 12 months. Descriptive summary of the data on this page, not a recommendation.
Momentum Oversold RSI (14) 29.9 (overbought above 70, oversold below 30)
Short interest 13.3% of float FINRA settlement Oct 30, 2026
SMA 10 — SMA 20 — SMA 50 — SMA 200 —
Price details unavailable for this range. ×
Chart loads when this section enters view.
Dated chart events require JavaScript on this compact chart. Open the full chart for dated events .
Text price and event history 6M plotted price range (ET) Range 6M First date — Last date — Open — High — Low — Close — Volume — Plotted bars 0
Plotted OHLCV bars No price bars are available for this range.
Event records Event records load after the price chart.
Split-adjusted daily prices · Price as of —
Initial 6M price range summary Range 6M First close — Last close — High — Low — Volume —
Open $11.16 Nov 18, 2026 session
Previous close $11.14 Nov 17, 2026 close
Day range $10.69 – $11.35 Nov 18, 2026 session
52-week range $10.03 – $19.99 Through Nov 18, 2026
Volume 1.41M Nov 18, 2026 session
Average volume (30 calendar days, 0 sessions) — Through Nov 18, 2026
Market cap $1.54B
P/E (TTM) negative earnings —
Forward P/E —
EPS (TTM) stale vendor snapshot —
Dividend yield data unavailable —
Beta (5-year monthly vs SPY) 1.14
Price history NVCR · NASDAQ · USD
Split-adjusted · volume in shares
Price history unavailable Retry
Notable price movement — · Notable price movement not available
Options flow — · Options flow not available
Q Score — · Q Score not available
Industry comparison — · Industry comparison not available
Upcoming events — · Upcoming events not available
Analyst consensus Neutral
0 Strong Buy
2 Buy
3 Neutral
0 Sell
0 Strong Sell
Based on 5 active firms as of Nov 19, 2026 (365-day activity window)
12-month price targets (third-party analysts) Low $17.00
Average $25.20
High $52.00
As of Nov 19, 2026 across 5 active firms with targets. Targets are published by third-party analysts, not by Quantellect.
Full analyst forecast →
Earnings history EPS, last 8 quarters −2.00 −1.50 −1.00 −0.50 0.00 FY ’24 Q1 ’25 Q2 ’25 Q3 ’25 FY ’25 Q1 ’26 Q2 ’26 Q3 ’26
Estimate Beat Miss Match
Fiscal period Est. Actual Result
Q3 2026 −$0.23 −$0.09 —
Q2 2026 — −$0.13 —
Q1 2026 — −$0.62 —
Annual 2025 — −$1.22 —
Q3 2025 — −$0.33 —
Q2 2025 — −$0.36 —
Q1 2025 — −$0.31 —
Annual 2024 −$0.36 −$1.56 —
Smart-money activity In the last 60 days: 3 insider sales and 0 purchases. Last quarter: 0 new 13F positions. No congressional trades in 90 days.
Date Type Who Action Amount Source
Nov 9, 2026 Insider sell Brackmann Christoph Sell $94.4K Form 4 Nov 9, 2026 Insider sell Paravasthu Mukund Sell $39.6K Form 4 Nov 2, 2026 Insider sell Puri Michal Nath Sell $8.7K Form 4 Jun 4, 2026 Insider sell Leonard Frank X Sell $614.6K Form 4 Jun 2, 2026 Insider sell Stafford Kristin Sell $46.4K Form 4 Jun 2, 2026 Insider sell Ocean Allyson J Sell $46.4K Form 4 Jun 2, 2026 Insider sell Scannell Timothy J Sell $46.4K Form 4 Jun 2, 2026 Insider sell VERNON W ANTHONY Sell $46.4K Form 4 Jun 2, 2026 Insider sell LEUNG GABRIEL Sell $46.4K Form 4 All smart-money activity →
News and press releases Year All 2026 2025 Nov 13, 2026, 11:30 AM ET Nov 9, 2026, 7:00 AM ET Oct 29, 2026, 7:00 AM ET Oct 28, 2026, 7:00 AM ET Feb 19, 2025, 6:32 AM ET All NVCR news → Company profile NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer,
CEO Mr. Frank Leonard
Headquarters Baar, Switzerland
Employees 1,605
IPO date Oct 2, 2015
Sector Healthcare
Industry Medical Devices Q Score — · Q Score not available
Upcoming events — · Upcoming events not available
Analyst consensus Neutral
0 Strong Buy
2 Buy
3 Neutral
0 Sell
0 Strong Sell
Based on 5 active firms as of Nov 19, 2026 (365-day activity window)
12-month price targets (third-party analysts) Low $17.00
Average $25.20
High $52.00
As of Nov 19, 2026 across 5 active firms with targets. Targets are published by third-party analysts, not by Quantellect.
Full analyst forecast →
Earnings history EPS, last 8 quarters −2.00 −1.50 −1.00 −0.50 0.00 FY ’24 Q1 ’25 Q2 ’25 Q3 ’25 FY ’25 Q1 ’26 Q2 ’26 Q3 ’26
Estimate Beat Miss Match
Fiscal period Est. Actual Result
Q3 2026 −$0.23 −$0.09 —
Q2 2026 — −$0.13 —
Q1 2026 — −$0.62 —
Annual 2025 — −$1.22 —
Q3 2025 — −$0.33 —
Q2 2025 — −$0.36 —
Q1 2025 — −$0.31 —
Annual 2024 −$0.36 −$1.56 —
Company profile NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer,
CEO Mr. Frank Leonard
Headquarters Baar, Switzerland
Employees 1,605
IPO date Oct 2, 2015
Sector Healthcare
Industry Medical Devices